Abstract Wide variation in outcomes is observed for patients with hormone-receptor-positive metastatic breast cancer (MBC) receiving first-line CDK4/6 inhibitors plus endocrine therapy (CDK4/6i+ET). Although front-line escalation strategies are beginning to enter clinical practice, assigning patients to intensified or...
Luca Boscolo Bielo, F. Sánchez-Vega, Subhiksha Nandakumar et al.· Research Square· 0 citations
The data suggest that despite the heterogeneity in CRC, genomic evolution increases the impact of recurrent alterations, and integrating information about tumor primary location and genomics can be used to predict organ-specific metastasis risk.
Paolo Manca, H. Walch, Jierui Xu et al.· Cancer Cell· 1 citation
Together, these data show that ZFP36L2 acts as an important molecular switch that couples stress sensing with phenotypic plasticity, which in turn drives cellular dedifferentiation essential for re-establishing the ISC state during wound healing and metastasis.
Qi Jiang, Manisha S. Raghavan, Aileen M. Rodriguez et al.· Nature· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.